Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient and treatment characteristics

From: Prognostic values of mid-radiotherapy 18F-FDG PET/CT in patients with esophageal cancer

  Number Percent
Patient characteristics
 Age at treatment (yrs), median (range) 69.2 (46.4–86.8)
 Sex
  Female 3 14.3
  Male 18 85.7
 ECOG PS
  0–1 12 57.1
  2 9 42.9
 Pathology
  Squamous cell carcinoma 21 100.0
  Adenocarcinoma 0 0.0
 Site
  Upper thoracic (UI 20–25 cm) 5 23.8
  Middle thoracic (UI 25–30 cm) 9 42.9
  Lower thoracic (UI 30–40 cm) 7 33.3
 Stage
  I 1 4.8
  IIB 4 19.0
  IIIA 3 14.3
  IIIB 7 33.3
  IIIC 6 28.6
Treatment characteristics
 Aim
  Definitive 17 81.0
  Preop 4 19.0
 Concurrent chemotherapy 19 90.5
 Chemotherapy regimen (n = 19)
  5-Fluorouracil+cisplatin 18 94.7
  5-Fluorouracil monotherapy 1 5.3
 RT modality
  IMRT 21 100.0
  3D-CRT 0 0.0
 Median total dose (Gy), median (range) 63 (44.1–69.3)
 Median fraction dose (Gy), median (range) 2.1 (1.8–2.1)
 Fractions of RT completed before mid-radiotherapy PET (fractions), median (range) 11 (9–12)
 Dose of RT completed before mid-radiotherapy PET (Gy), median (range) 23.1 (18.9–25.2)
  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, UI upper incisor, RT radiotherapy, IMRT intensity-modulated radiotherapy, 3D-CRT 3 dimensional-conformal radiotherapy